Researcher.Life Logo

Ca-A Cancer Journal for Clinicians : Impact Factor & More

eISSN: 1542-4863pISSN: 0007-9235

Key Metrics

CiteScore
716.2
Impact Factor
>= 25
SNIP
173.93
Recommended pre-submission checks
Powered by Paperpal by Editage

Ca-A Cancer Journal for Clinicians Journal Specifications

Overview
Publisher WILEY
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year1950
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Ca-A Cancer Journal for Clinicians ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Ca-A Cancer Journal for Clinicians

Radiotherapy followed by adjuvant temozolomide improves survival for patients with aggressive IDH-mutated anaplastic glioma.
  • 1 Mar 2026
  • CA: a cancer journal for clinicians
Targeting tumor suppressor gene co-mutations in EGFR-mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification.
  • 1 Mar 2026
  • CA: a cancer journal for clinicians
Ethical considerations of genetic and genomic testing in pediatric oncology: A narrative review.
  • 1 Mar 2026
  • CA: a cancer journal for clinicians
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.
  • 1 Mar 2026
  • CA: a cancer journal for clinicians
Nonpharmacologic interventions for managing distress, anxiety, and depression for patients with cancer and their family caregivers: A systematic review and meta-analysis.
  • 1 Mar 2026
  • CA: a cancer journal for clinicians
Correction to "American Cancer Society's report on the status of cancer disparities in the United States, 2025".
  • 1 Mar 2026
  • CA: a cancer journal for clinicians
Radiotherapy followed by adjuvant temozolomide improves survival for patients with aggressive IDH-mutated anaplastic glioma.
  • 1 Mar 2026
  • CA: a cancer journal for clinicians
Targeting tumor suppressor gene co-mutations in EGFR-mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification.
  • 1 Mar 2026
  • CA: a cancer journal for clinicians
Ethical considerations of genetic and genomic testing in pediatric oncology: A narrative review.
  • 1 Mar 2026
  • CA: a cancer journal for clinicians
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.
  • 1 Mar 2026
  • CA: a cancer journal for clinicians
Nonpharmacologic interventions for managing distress, anxiety, and depression for patients with cancer and their family caregivers: A systematic review and meta-analysis.
  • 1 Mar 2026
  • CA: a cancer journal for clinicians
Correction to "American Cancer Society's report on the status of cancer disparities in the United States, 2025".
  • 1 Mar 2026
  • CA: a cancer journal for clinicians

FAQs on Ca-A Cancer Journal for Clinicians